Results 191 to 200 of about 843,559 (297)

Novel targets in headache: A narrative review

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This narrative review summarizes novel applications for the use of calcitonin gene‐related peptide (CGRP)‐targeted therapies that go beyond migraine, the latest updates with respect to targeting pituitary adenylate cyclase‐activating peptide (PACAP) as therapeutic in migraine, as well as exploring other more recently ...
Adriana Della Pietra   +5 more
wiley   +1 more source

Nemolizumab for Pruritus Control in Cutaneous T‐Cell Lymphoma: A Case Series

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela   +2 more
wiley   +1 more source

Long‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and MAIC

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
A matching‐adjusted indirect treatment comparison (MAIC) was conducted, comparing approved biologics for long‐term (48–52 weeks) treatment of moderate‐to‐severe hidradenitis suppurativa (HS). Using weighted patient‐level trial data allowed re‐estimation of relative bimekizumab efficacy compared with aggregate secukinumab and adalimumab trial data ...
Thrasyvoulos Tzellos   +9 more
wiley   +1 more source

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The majority of bimekizumab‐treated patients shifted from severe to mild and moderate IHS4 stages, and nearly 25% achieved an IHS4 of 0 by Week 48. Bimekizumab led to clinically meaningful improvements across IHS4 outcome measures. These data highlight an opportunity to address the need for effective treatments against draining tunnels.
Thrasyvoulos Tzellos   +15 more
wiley   +1 more source

‘Mindshifting’ type 1 diabetes care: Preparing UK services for the era of disease‐modifying therapy

open access: yes
Diabetic Medicine, EarlyView.
Parth Narendran   +4 more
wiley   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran   +2 more
wiley   +1 more source

Artificial intelligence-assisted design of MAGE-A4 ×CD16 T-cell receptor-like natural killer cell engagers. [PDF]

open access: yesMAbs
Liu Y   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy